Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Advanced Breast Cancer
Phase 1
18 Years
N/A
18 Years
N/A
Not Enrolling
Female
Advanced Breast Cancer
Female
Advanced Breast Cancer
Trial Information
Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Advanced Breast Cancer
For additional information, please contact the BMS oncology clinical trial information
service at 855-216-0126 or email MyCancerStudyConnect@emergingmed.com. Please visit
www.BMSStudyConnect.com for more information on clinical trial participation.
Inclusion Criteria:
- Female with advanced breast cancer previously treated with a taxane and an
anthracycline
- No pleural or pericardial effusion
- Not receiving anticoagulants
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
To identify major toxicities
Outcome Time Frame:
throughout the study
Safety Issue:
Yes
Principal Investigator
Bristol-Myers Squibb
Investigator Role:
Study Director
Investigator Affiliation:
Bristol-Myers Squibb
Authority:
United States: Food and Drug Administration
Study ID:
CA180-004
NCT ID:
NCT00452673
Start Date:
June 2007
Completion Date:
October 2012
Related Keywords:
- Advanced Breast Cancer
- Breast Neoplasms
Name | Location |
|---|---|
| City of Hope National Medical Center | Los Angeles, California 91010 |
| Seattle Cancer Care Alliance | Seattle, Washington 98109 |
| New York Presbyterian Hospital | New York, New York 10021 |
| Northwestern University Feinberg School of Medicine | Chicago, Illinois 60611 |
